Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists

In response to concern about the reported frequency of ergot‐associated valvulopathy in patients with Parkinson's disease (PD), Eli Lilly and Company updated the Risk Minimization Program for pergolide, changing the Summary of Product Characteristics (SmPC) and distributing a Dear Doctor Letter...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of neurology 2007-06, Vol.14 (6), p.644-649
Hauptverfasser:	LLedó, A., Dellva, M. A., Strombom, I. M., Wilkie, J. L., Jungemann, Mark E., Royer, M. G., Simmons, V. E., Cavazzoni, P. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	adverse effects Antiparkinson Agents - adverse effects Awareness change in physician practice patterns Data Collection drug labeling change Europe Female Heart Valve Diseases - chemically induced Humans International Cooperation Male Neurology Parkinson's disease pergolide Pergolide - adverse effects Practice Patterns, Physicians risk minimization plan survey valvulopathy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!